Analyst Reco. Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Market Closed - Nyse Other stock markets 21:00:02 11/09/2024 BST			5-day change	1st Jan Change
16.97 ^USD	+1.74%		+3.98%	-11.15%

09-04	Transcript : Arcus Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM
08-27	Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Lowers Price Target on Arcus Biosciences to $44 From $50, Maintains Buy Rating	06-24	MT
Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating	06-03	MT
Mizuho Adjusts Arcus Biosciences' Price Target to $42 From $51, Keeps Buy Rating	01-30	MT
Wedbush Lowers Arcus Biosciences' PT to $30 From $36 After Announced Plans to Discontinue Enrollment for Phase 3 ARC-10 Study; Keeps Outperform Rating	01-30	MT
Morgan Stanley Cuts Price Target on Arcus Biosciences to $35 From $38, Maintains Overweight Rating	11-13	MT
Cantor Fitzgerald Adjusts Arcus Biosciences' Price Target to $36 From $46, Maintains Overweight Rating	11-08	MT
Citigroup Adjusts Price Target on Arcus Biosciences to $44 From $41, Maintains Buy Rating	24/08/23	MT
Morgan Stanley Trims Price Target on Arcus Biosciences to $38 From $40, Maintains Overweight Rating	08/08/23	MT
Cantor Fitzgerald Reiterates Arcus Biosciences' Overweight Rating, $46 Price Target	12/07/23	MT
Citigroup Adjusts Arcus Biosciences Price Target to $41 From $40, Maintains Buy Rating	26/05/23	MT
Barclays Adjusts Price Target on Arcus Biosciences to $35 From $60, Maintains Overweight Rating	21/12/22	MT
Citigroup Adjusts Arcus Biosciences' Price Target to $42 From $37, Keeps Buy Rating	20/12/22	MT
Citigroup Lowers Price Target on Arcus Biosciences to $37 From $40, Maintains Buy Rating	23/11/22	MT
BofA Securities Starts Arcus Biosciences at Neutral With $33 Price Target	18/11/22	MT
SVB Securities Adjusts Price Target on Arcus Biosciences to $38 From $40, Maintains Outperform Rating	03/11/22	MT
Berenberg Bank Adjusts Arcus Biosciences Price Target to $60 From $68, Maintains Buy Rating	03/11/22	MT
Morgan Stanley Starts Arcus Biosciences at Overweight With $40 Price Target	11/10/22	MT
Goldman Sachs Adjusts Arcus Biosciences' Price Target to $29 From $28, Maintains Neutral Rating	04/08/22	MT
SVB Securities Adjusts Arcus Biosciences' Price Target to $49 from $66, Keeps Outperform Rating	04/08/22	MT
Wedbush Adjusts Price Target on Arcus Biosciences to $36 From $42, Keeps Outperform Rating	04/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Analyst Reco.

Filters